16 completed, 3 active not recruiting, 2 terminated, 1 unknown. 23 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 16, Active not recruiting 3, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 7 | Active not recruiting 3, Completed 3, Terminated 1 |
Follow Thyroid Cancer, Papillary: new trials by email Literature Review of Thyroid Cancer, Papillary trials Research Report on Thyroid Cancer, Papillary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer 177Lu-DOTA-EB-FAPI 1 radionuclide therapy, 177Lu-DOTA-EB-FAPI 2 radionuclide therapy, 177Lu-DOTA-EB-FAPI 3 radionuclide therapy - Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma | Phase 1 | Completed | The First Affiliated Hospital of Xiamen University | 12 | 2022-06-15 | 2025-04-01 |
| A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion - Solid Tumor, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Famewave Ltd. | 79 | 2021-03-19 | 2024-12-27 |
| Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib - Thyroid Carcinoma, Thyroid Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 8 | 2020-06-26 | 2025-09-08 |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Selpercatinib - Medullary Thyroid Cancer, Infantile Myofibromatosis | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 36 | 2019-06-13 | 2026-01-06 |
| A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. Imatinib Oral Tablet - Papillary Thyroid Cancer | Phase 1 | Terminated | AHS Cancer Control Alberta | 14 | 2018-09-18 | 2025-06-27 |
| Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging IV adminstration of EMI-137, Multispectral Fluorescence Reflectance Imaging, Spectroscopy - Papillary Thyroid Cancer, Lymph Node Metastases | Phase 1 | Completed | University Medical Center Groningen | 19 | 2018-06-20 | 2024-04-16 |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) LOXO-292 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 857 | 2017-05-02 | 2026-04-16 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 590 | 2017-03-17 | 2025-05-31 |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options Entrectinib - Solid Tumors, CNS Tumors | Phase 1 / Phase 2 | Active not recruiting | Hoffmann-La Roche | 69 | 2016-05-03 | 2026-09-23 |
| Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery pazopanib hydrochloride, iodine I 131 - Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer | Phase 1 | Completed | University of Washington | 6 | 2011-12-01 | 2015-11-05 |
| Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis - Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 127 | 2010-09-09 | 2021-07-15 |
| A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors rosiglitazone, XL184 - Papillary Thyroid Cancer, Follicular Thyroid Cancer | Phase 1 | Completed | Exelixis | 40 | 2010-04-01 | 2013-09-19 |
| S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors docetaxel, vandetanib, proteomic profiling - Breast Cancer, Head and Neck Cancer | Phase 1 | Withdrawn | SWOG Cancer Research Network | 2008-09-01 | 2017-04-24 | |
| Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors bortezomib, paclitaxel - Breast Cancer, Colorectal Cancer | Phase 1 | Completed | University of Medicine and Dentistry of New Jersey | 16 | 2007-03-01 | 2011-05-10 |
| Study of XL281 in Adults With Solid Tumors XL281, famotidine - Cancer, Non-small-cell Lung Cancer | Phase 1 | Completed | Exelixis | 180 | 2007-02-01 | 2011-10-13 |
| Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer HPPH, photodynamic therapy, conventional surgery - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip | Phase 1 | Completed | Roswell Park Cancer Institute | 15 | 2006-10-19 | 2022-07-25 |
| NGR-TNF in Treating Patients With Advanced Solid Tumors CNGRC peptide-TNF alpha conjugate - Colorectal Cancer, Head and Neck Cancer | Phase 1 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 70 | 2004-09-01 | 2012-09-24 |
| Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer conventional surgery, radiofrequency ablation - Head and Neck Cancer | Phase 1 | Unknown | University of California, San Francisco | 2004-09-01 | 2013-09-20 | |
| Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases boronophenylalanine-fructose complex, sodium borocaptate, conventional surgery - Colorectal Cancer, Head and Neck Cancer | Phase 1 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 27 | 2003-04-01 | 2012-01-20 |
Showing 20 of 23. Sign in to see all of them.
Thyroid Neoplasms (14) · Adenocarcinoma, Follicular (11) · Carcinoma, Non-Small-Cell Lung (10) · Head and Neck Neoplasms (10) · Carcinoma, Medullary (8) · Colonic Neoplasms (8) · Breast Neoplasms (7) · Salivary Gland Neoplasms (7) · Colorectal Neoplasms (6) · Neoplasms (6) · Lung Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Thyroid Carcinoma, Anaplastic (5) · Carcinoma, Renal Cell (4)
Adenocarcinoma (22) · Adenocarcinoma, Papillary (22) · Carcinoma (22) · Neoplasms by Histologic Type (22) · Neoplasms, Glandular and Epithelial (22) · Endocrine Gland Neoplasms (20) · Endocrine System Diseases (20) · Neoplasms by Site (20) · Thyroid Diseases (20) · Neoplasms (17) · Head and Neck Neoplasms (13) · Neoplasms, Germ Cell and Embryonal (13) · Neoplasms, Nerve Tissue (13) · Neuroectodermal Tumors (13) · Neuroendocrine Tumors (11)
Iodine-131 (2) · Trastuzumab (2) · selpercatinib (2) · 1-phenyl-3,3-dimethyltriazene (1) · 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (1) · 4-boronophenylalanine-fructose (1) · Azacitidine (1) · Bortezomib (1) · Congresses as Topic (1) · Docetaxel (1) · Famotidine (1) · Imatinib Mesylate (1) · Interleukin-12 (1) · Interleukin-12 Subunit p35 (1) · Lenalidomide (1)
National Cancer Institute (NCI) (3) · Eli Lilly and Company (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Exelixis (2) · Hoffmann-La Roche (2) · AHS Cancer Control Alberta (1) · Aminex Therapeutics, Inc. (1) · Famewave Ltd. (1) · Lucille P. Markey Cancer Center at University of Kentucky (1) · Memorial Sloan Kettering Cancer Center (1) · Roswell Park Cancer Institute (1) · SWOG Cancer Research Network (1) · The First Affiliated Hospital of Xiamen University (1) · University Medical Center Groningen (1) · University of California, San Francisco (1)
United States (17) · Germany (6) · Canada (5) · Spain (5) · France (4) · Italy (4) · United Kingdom (4) · Australia (3) · China (3) · Hong Kong (3) · Netherlands (3) · South Korea (3) · Denmark (2) · Israel (2) · Japan (2)
Alan L Ho, MD, PhD (1) · Anthony W. Tolcher, MD (1) · Chih-Yi Liao (1) · Cornelis J. A. Punt, MD, PhD (1) · Electron Kebebew, MD (1) · Gooitzen M van Dam, MD, PhD (1) · Haojun Chen, MD, PhD (1) · Hassan Arshad (1) · Jennifer Spratlin, MD FRCPC (1) · Kenneth Ain, MD (1) · Laura Chow (1) · Michael Armstrong, MD (1) · Michael Schickler, PhD (1)
PMID 37934000, PMID 17985341, PMID 19372041, PMID 19602035, PMID 19735988, PMID 20145168, PMID 21367608, PMID 23868427, PMID 24827131, PMID 28662033, PMID 31838007, PMID 32846060, PMID 32846061, PMID 34088726, PMID 34118197, PMID 34118198, PMID 35389070, PMID 35395680, PMID 35715405, PMID 35930972, PMID 35962206, PMID 36108661, PMID 36122315, PMID 36657661, PMID 37171634, PMID 37265412, PMID 37282666, PMID 37916501, PMID 38009200, PMID 38017325, PMID 38661071, PMID 39085487, PMID 39094065, PMID 39471424, PMID 39983053, PMID 40086048, PMID 40639400, PMID 41886723, PMID 42874021
2023 (2), 2016 (1), 2017 (1), 2019 (1), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), P30CA014599 (1), P30CA015704 (1), P30CA072720 (1), U01CA076576 (1), U10CA180821 (1)